On July 6, XtalPi Holdings rose 5.95% in regular trading, trading at HK$8.45/share, with turnover of HK$262 million. The rally was driven by continued CXO sector strength and multiple company-level positive developments.

On July 2, XtalPi granted approximately 34.98 million share options and 8.68 million restricted share units at an exercise price of HK$7.48, signaling management confidence in long-term value creation. Prior to this, the company announced a strategic AI drug discovery partnership with an international biopharmaceutical company valued at over $400 million, targeting an oral small-molecule GPCR therapy. A $100 million share buyback program has been actively implemented since June 10. Additionally, the deployment of the company's AI autonomous experiment workstation at Sinopec marks substantive progress in extending its AI+robotics platform into materials science.

Within the Life Sciences Tools and Services sector, peers also saw broad gains, with WUXI XDC up 6.48%, GENSCRIPT BIO up 6.17%, WUXI BIO up 3.09%, WUXI APPTEC up 3.01%, and INSILICO up 1.66%.

(The above content is based on publicly available market information, generated by a program or algorithm, and is intended solely as a stock movement alert. It does not constitute investment advice or a basis for trading decisions.)